Mounjaro Constipation: SURPASS-1 Rates, Mechanism & Evidence-Based Relief Protocol

Constipation is a recognized but lower-rate gastrointestinal side effect on Mounjaro (tirzepatide for type 2 diabetes). The SURPASS-1 monotherapy pivotal trial in diet-and-exercise-treated T2D reported constipation in roughly 6–7% of patients on Mounjaro 15 mg vs. about 1–2% on placebo over 40 weeks, with gastrointestinal events overall (nausea, diarrhea, vomiting, constipation) dominating the safety profile^[2]. The mechanism is the same dual GIP + GLP-1 receptor activation that powers the appetite-and-glycemic effect: slowed gastric emptying plus reduced lower-GI motility^[5][6]. What makes the T2D context different from the obesity-dose Zepbound conversation is that roughly half of long-standing T2D patients have baseline diabetic gastroparesis or autonomic neuropathy that already slows gut transit — Mounjaro can unmask or worsen what was previously subclinical. This guide covers what SURPASS-1 and SURPASS-2 actually measured, why the diabetic-gastroparesis backdrop matters, the metformin counterweight, the evidence-based relief protocol, and the FDA-label ileus red flags that warrant an urgent call to your prescriber.

The honest short answer for Mounjaro patients

Mounjaro is the same molecule as Zepbound — tirzepatide — but it’s the brand approved for type 2 diabetes rather than chronic weight management. The reported constipation rate on Mounjaro tends to run lower than on Zepbound at the same milligram dose, for two reasons. First, T2D patients enrolled in the SURPASS trials had a different baseline GI symptom profile than the obesity-only patients in SURMOUNT — many were already on metformin (which causes diarrhea, partially counterbalancing the constipation signal), and many had subclinical diabetic gastroparesis that may not have been adjudicated as a new adverse event. Second, the trial endpoints and adjudication windows differed across the two programs. In SURPASS-1, the most common adverse events on Mounjaro were nausea (12–18%), diarrhea (12–14%), and vomiting (2–6%), with constipation in the lower single digits^[2]. That said, if you’re titrating up on Mounjaro and bowel movements have shifted from daily to every 3–4 days, the underlying mechanism is identical to Zepbound and the relief protocol is the same: a deliberate fiber-fluid-walking routine layered on from the first dose step, not improvised in week six when you’re already miserable.

What SURPASS-1 and SURPASS-2 actually measured

SURPASS-1 was the 40-week double-blind, placebo-controlled phase 3 pivotal trial of tirzepatide monotherapy in 478 adults with T2D inadequately controlled by diet and exercise alone, with patients randomized 1:1:1:1 to 5 mg, 10 mg, 15 mg of tirzepatide, or placebo^[2]. The Rosenstock 2021 Lancet publication reported the gastrointestinal adverse-event profile:

• Nausea — 12–18% across the three tirzepatide doses vs. 6% on placebo.
• Diarrhea — 12–14% on tirzepatide vs. 8% on placebo.
• Vomiting — 2–6% on tirzepatide vs. 2% on placebo.
• Constipation — reported in the lower single digits in the safety table, with the Mounjaro FDA label Section 6.1 pooling SURPASS-1/-2/-3/-5 to report approximately 6–7% at the 15 mg dose vs. background placebo rates of 1–2%^[1].

SURPASS-2 was the open-label 40-week head-to-head trial of tirzepatide (5, 10, 15 mg) vs. semaglutide 1 mg in 1,879 patients with T2D on background metformin^[3]. Tirzepatide produced larger HbA1c reductions and larger weight loss at all three doses vs. semaglutide 1 mg, and the GI tolerability comparison was striking for its similarity: nausea 17–22% on tirzepatide vs. 18% on semaglutide; diarrhea 13–16% vs. 12%; vomiting 6–10% vs. 8%. Constipation was reported at broadly comparable rates between the two drugs in this T2D head-to-head — the often-cited gap in constipation reporting between tirzepatide and semaglutide is more visible at the higher obesity-indication doses (SURMOUNT-1 vs. STEP-1) than at the lower T2D-indication doses. For the full cross-indication comparison see our tirzepatide constipation evidence review covering all three SURPASS and SURMOUNT trials.

The Mounjaro FDA label Section 6.1 pools constipation rates across the SURPASS registration trials and reports figures consistent with the per-trial safety tables^[1]. The label flags constipation among the most-common adverse reactions occurring at higher rates than placebo across all three approved Mounjaro doses (5, 10, 15 mg).

Mechanism — dual GIP + GLP-1 gastric-emptying delay

Tirzepatide is a unimolecular dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Activation of GLP-1 receptors on enteric neurons slows gastric emptying and reduces overall gut motility — the same mechanism that suppresses appetite and reduces post-prandial glucose excursions^[6]. Marathe and colleagues’ 2013 Peptides review summarized the physiology: native GLP-1 and pharmacologic GLP-1 receptor agonists delay gastric emptying in a dose-dependent fashion, and this deceleration extends to the small intestine and colon^[6]. The added GIP agonism in tirzepatide compounds the motility effect. Urva and colleagues’ 2020 pharmacokinetic study in Diabetes, Obesity and Metabolism documented that tirzepatide produces a transient but profound gastric-emptying delay following dose escalation, with the magnitude consistent across selective long-acting GLP-1 receptor agonists^[5].

In practical terms: food sits in the stomach longer, the small bowel moves contents along more slowly, and the colon has more time to reabsorb water from stool. Drier stool plus slower transit equals the textbook recipe for constipation. The same mechanism that helps you lower HbA1c and lose weight also helps you go less often.

Why T2D context matters — the diabetic-gastroparesis backdrop

Diabetic gastroparesis — delayed gastric emptying caused by autonomic neuropathy of the vagus nerve and enteric nervous system — is one of the most under-recognized complications of long-standing type 2 diabetes. Population studies estimate that as many as half of patients with T2D of 10+ years duration have objectively delayed solid-meal gastric emptying on scintigraphy, though only a fraction develop the classic symptomatic syndrome (early satiety, post-prandial fullness, bloating, nausea, vomiting, chronic constipation from broader autonomic neuropathy). This matters for Mounjaro patients in three concrete ways:

• Baseline overlap with Mounjaro side effects. Many new Mounjaro patients are starting from a baseline where they already have mild slow-transit constipation from autonomic dysfunction. Layering tirzepatide’s pharmacologic gastric-emptying delay on top can produce a step-change in symptom severity that wouldn’t happen in an obesity-only patient.
• Symptoms that warrant evaluation, not just tolerance. If you have known diabetic gastroparesis or autonomic neuropathy, new or worsening constipation on Mounjaro should be discussed with your prescriber rather than self-managed indefinitely. The threshold to investigate is lower than for an otherwise-healthy patient.
• The titration curve is your friend. Mounjaro dosing starts at 2.5 mg for 4 weeks before stepping up — the slow titration is specifically designed to let the gut adapt before higher doses are introduced. Patients with diabetic gastroparesis may benefit from staying at each dose step for 8 weeks rather than 4 before escalating, in consultation with their prescriber.

Mounjaro + metformin — opposing GI effects

Most T2D patients prescribed Mounjaro are also taking metformin as first-line background therapy. Metformin’s most common adverse effect is diarrhea, particularly in the first 4–8 weeks of therapy and with dose escalation. Mounjaro’s most common long-term GI effect skews toward constipation as the gut adapts. Many patients on the combination report that the two effects partially cancel each other out, with a net bowel pattern closer to baseline than either drug alone would produce.

Practical implications:

• Don’t stop metformin to fix Mounjaro diarrhea. Metformin has clear cardiovascular and mortality benefits in T2D documented across decades of trials. Adjusting metformin to manage Mounjaro side effects should be a prescriber-led decision, not a self-directed change.
• Watch for the shift around month 3. Early in combination therapy, the metformin diarrhea often dominates. As the gut adapts to metformin and Mounjaro reaches higher doses, the constipation signal can emerge. If you started constipated and shifted to diarrhea (or vice versa) at month 2–3, that’s the typical pattern.
• Extended-release metformin reduces GI burden. If metformin diarrhea was your dominant problem before starting Mounjaro, ask your prescriber about switching from immediate-release to extended-release (Glucophage XR or Glumetza). The XR formulation reduces GI side effects in many patients.

Practical relief protocol: fiber, fluids, walking, magnesium

The first-line relief protocol is the same conservative, well-supported regimen used for any GLP-1-class constipation. It costs nothing, has no drug interactions, and is what most gastroenterologists recommend before any laxative.

Soluble fiber 25–35g/day

Soluble fiber (psyllium husk, oat beta-glucan, ground flax, chia seeds, pectin) softens stool and forms transit-lubricating gels in the colon. On a typical T2D meal plan, hitting 25–35g/day requires deliberate planning — you cannot get there by accident.

• Psyllium husk (Metamucil) — 1 tablespoon (~5g soluble fiber) in a full 8 oz glass of water, 1–3 times daily. The water is non-negotiable; psyllium without enough fluid can worsen constipation. Psyllium has the bonus of modest LDL-cholesterol lowering, useful for many T2D patients.
• Ground flaxseed — 1–2 tablespoons in yogurt, oatmeal, or a smoothie. ~3g fiber per tablespoon plus omega-3s.
• Chia seeds — 1–2 tablespoons, ideally hydrated for 10 minutes in liquid before eating. ~5g fiber per tablespoon.
• High-fiber whole foods — raspberries, pears with skin, avocado, lentils, black beans, bran cereal.

Use our GLP-1 fiber calculator to plan a day that actually hits 25–35g; without planning, most Mounjaro patients land between 8–12g.

Hydration 2.5–3L/day

Fiber without enough fluid is a worse outcome than no fiber. The standard recommendation for an adult on a GLP-1 is 2.5–3 liters of non-caffeinated fluid per day — this is also the volume that protects against the Mounjaro FDA label Section 5.3 acute kidney injury risk associated with dehydration from GI adverse events^[1]. T2D patients on SGLT2 inhibitors (Jardiance, Farxiga, Invokana) need to be even more careful about hydration because those drugs cause obligate osmotic diuresis on top of the GLP-1 thirst suppression.

Walking and gentle movement

Physical activity stimulates colonic motility. A 20–30 minute walk after a meal is one of the highest-leverage, zero-side-effect interventions for sluggish bowel transit. The post-meal walk also improves post-prandial glucose excursions in T2D — double benefit.

Magnesium citrate 200–400 mg (second line)

Mori and colleagues’ 2019 randomized double-blind placebo-controlled trial in the Journal of Neurogastroenterology and Motility demonstrated that oral magnesium oxide improved both stool frequency and consistency in chronic constipation patients vs. placebo over 28 days^[7]. Magnesium citrate is the better-absorbed form for daily use. Start at 200 mg at bedtime, titrate up to 400 mg if needed.

Caution for T2D patients: diabetic nephropathy is a common late complication of T2D, and impaired kidneys can’t excrete excess magnesium. If your eGFR is below 60 mL/min/1.73m² (CKD stage 3+), check with your prescriber before starting magnesium supplementation. Hypermagnesemia from oral supplements that healthy kidneys would excrete can become symptomatic in CKD.

Polyethylene glycol 3350 (MiraLAX)

PEG 3350 is the over-the-counter osmotic laxative most gastroenterologists recommend for adult constipation. It’s non-absorbed, has minimal side effects, and is safe for long-term use. Dose: 17g (one capful) in 8 oz of fluid once daily; can be increased to twice daily if needed.

Red flags: when to call your prescriber

The Mounjaro FDA label includes ileus as a postmarketing adverse reaction reported in patients on tirzepatide, consistent with the class effect documented across GLP-1 receptor agonists^[1]. Ileus — the functional shutdown of normal bowel peristalsis — can mimic ordinary tirzepatide constipation in its early presentation but progresses to a medical emergency. The distinguishing features:

• No bowel movement for 5+ days AND no passage of gas (this is the cardinal sign — obstipation is more concerning than just constipation).
• Progressive abdominal distension — visibly swollen abdomen that is firm to the touch.
• Severe abdominal pain, especially crampy or colicky pain in waves.
• Vomiting, particularly vomiting of bile (green/ yellow) or feculent (foul-smelling, dark) material.
• Inability to keep down fluids.

Any combination of these symptoms warrants urgent evaluation — call your prescriber immediately, or go to an emergency department if you cannot reach them quickly. Bring your medication or the label so the treating team knows you’re on tirzepatide. T2D-specific red flags also include severe hyperglycemia (since prolonged vomiting can disrupt usual oral hypoglycemic dosing) and signs of diabetic ketoacidosis (DKA), which is rare on Mounjaro alone but can occur in stress states like severe ileus.

Pancreatitis is another rare but serious consideration that the Mounjaro label flags in Section 5.2^[1]. Severe persistent abdominal pain that radiates to the back, with or without vomiting, warrants prompt evaluation regardless of whether constipation is the dominant symptom. For the broader differential between ileus, gastroparesis, and ordinary GLP-1 delayed emptying, see our GLP-1 side effect questions answered hub.

How Mounjaro compares to Zepbound on constipation

Mounjaro and Zepbound are the same molecule — tirzepatide — manufactured by the same company (Eli Lilly), shipped in identical KwikPen single-dose pens, with the same 2.5, 5, 7.5, 10, 12.5, and 15 mg dose strengths. The difference is regulatory: Mounjaro is the FDA-approved brand for type 2 diabetes; Zepbound is the FDA-approved brand for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity. See our Mounjaro vs. Zepbound disambiguation for the full breakdown.

Why constipation appears at different rates in the SURPASS (Mounjaro) vs. SURMOUNT (Zepbound) tables:

• Trial duration. SURMOUNT-1 ran 72 weeks vs. SURPASS-1 at 40 weeks. Longer follow-up captures more cumulative AE incidence.
• Population. SURMOUNT-1 enrolled adults with obesity (BMI ≥30) without T2D. SURPASS-1 enrolled adults with T2D inadequately controlled by diet and exercise alone. Different baseline GI symptoms and different concurrent medications.
• Background therapy. SURPASS-2, -3, and -5 required background metformin (and other oral agents in some arms); the metformin diarrhea partially masks emerging constipation signals. SURMOUNT trials had no metformin background.
• Adjudication and prompts. The two trial programs had different patient-reported AE prompts and different adjudication windows. Cross-trial comparison is order-of-magnitude rather than precise.

The bottom line: if you’re prescribed Mounjaro for T2D and constipation becomes intolerable, switching to Zepbound is not a relief lever — it’s the same drug. The right lever is the fiber-fluid-walking-magnesium protocol, slowing the titration cadence with your prescriber, or considering a different class of T2D therapy if the constipation truly cannot be managed.

Related research and tools

• Zepbound constipation: SURMOUNT-1 rates, mechanism, and relief — the obesity-indication sister article with the higher-dose SURMOUNT-1 safety table breakdown
• Tirzepatide constipation: causes, FDA-label rates, and evidence-based relief — the molecule-level synthesis covering both Mounjaro and Zepbound across all SURPASS and SURMOUNT trials
• Ozempic constipation: causes, FDA-label rates, and evidence-based relief — the semaglutide T2D-indication comparison with SUSTAIN-1 rates
• Mounjaro vs. Zepbound: same drug, different brands — why the same molecule has two FDA-approved brand names
• GLP-1 side effect questions answered — the Q&A hub with every common patient question
• GLP-1 side effect timeline tool — when each side effect peaks and resolves, by drug and week
• GLP-1 fiber calculator — plan a 25–35g/day fiber target on a T2D meal plan

Important disclaimer. This article is educational and does not constitute medical advice. Constipation management decisions on Mounjaro should always be made with your prescribing clinician, particularly if you have diabetic gastroparesis, autonomic neuropathy, diabetic nephropathy (CKD), heart failure, or are taking multiple other medications including insulin, sulfonylureas, SGLT2 inhibitors, or metformin. If you have any of the red flag symptoms listed above (no stool for 5+ days plus abdominal pain or vomiting, progressive distension, inability to pass gas), seek care promptly.